Tesamorelin Price Comparison

Live prices from 196 UK suppliers, from £13.00, compared side by side so you never overpay.

Growth hormone axis Prices checked
We compare prices & may earn a commission. We do not sell or supply any products. This page includes a featured supplier placement, which has not been independently verified or endorsed. Listing does not constitute a recommendation. Full disclosure.

We may earn a commission from the suppliers listed here. Read our full disclosure.

Best Price £20.00
Average £20.00
Highest £20.00
1 result
Best Price
Peptides2go logo
Peptides2go 50 /100 Confidence

Tesamorelin 6mg

In Stock 6mg
£20.00
FREE delivery

Compare another peptide

PeptideSupermarket® compares prices but doesn't sell products.

All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.

We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.

By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.

Tesamorelin Profile

Fda Approved FDA Approved

GHRH Analog | Visceral Fat Reduction

Overview

Tesamorelin is an FDA-approved synthetic GHRH analog designed for HIV-associated lipodystrophy treatment. It provides selective visceral fat targeting with 15-20% visceral fat reduction in clinical trials while preserving subcutaneous fat.

Mechanism of Action

Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat.

Key Benefits

  • FDA-approved formulation
  • Selective visceral fat targeting (15-20% reduction)
  • Proven clinical efficacy
  • Standardized dosing
  • 37% liver fat reduction in NAFLD
  • Preserved subcutaneous fat

Quick Stats

Typical Dose
1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy)
Frequency
Once daily (evening preferred for GH rhythm)
Cycle Duration
Continuous therapy for maintained benefits
Storage
Powder: 20-25°C. Egrifta SV: use immediately. Egrifta WR: room temp up to 7 days

Molecular Information

Molecular Weight
5,135.9 Da
Length
44 amino acids
Type
GHRH analog
Half-Life
26-38 minutes

Amino Acid Sequence

One-letter: HADGIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL
His
1

Histidine

Position 1

Ala
2

Alanine

Position 2

Asp
3

Aspartic Acid

Position 3

Gly
4

Glycine

Position 4

Ile
5

Isoleucine

Position 5

Phe
6

Phenylalanine

Position 6

Thr
7

Threonine

Position 7

Asn
8

Asparagine

Position 8

Ser
9

Serine

Position 9

Tyr
10

Tyrosine

Position 10

Arg
11

Arginine

Position 11

Lys
12

Lysine

Position 12

Val
13

Valine

Position 13

Leu
14

Leucine

Position 14

Gly
15

Glycine

Position 15

Gln
16

Glutamine

Position 16

Leu
17

Leucine

Position 17

Ser
18

Serine

Position 18

Ala
19

Alanine

Position 19

Arg
20

Arginine

Position 20

Lys
21

Lysine

Position 21

Leu
22

Leucine

Position 22

Leu
23

Leucine

Position 23

Gln
24

Glutamine

Position 24

Asp
25

Aspartic Acid

Position 25

Ile
26

Isoleucine

Position 26

Met
27

Methionine

Position 27

Ser
28

Serine

Position 28

Arg
29

Arginine

Position 29

Gln
30

Glutamine

Position 30

Gln
31

Glutamine

Position 31

Gly
32

Glycine

Position 32

Glu
33

Glutamic Acid

Position 33

Ser
34

Serine

Position 34

Asn
35

Asparagine

Position 35

Gln
36

Glutamine

Position 36

Glu
37

Glutamic Acid

Position 37

Arg
38

Arginine

Position 38

Gly
39

Glycine

Position 39

Ala
40

Alanine

Position 40

Arg
41

Arginine

Position 41

Ala
42

Alanine

Position 42

Arg
43

Arginine

Position 43

Leu
44

Leucine

Position 44

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Modifications

Modified with trans-3-hexenoic acid at N-terminus for enhanced stability

Research Indications

The following information is derived from published scientific literature and is provided for educational and research reference purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. These peptides are not approved for human use and are sold exclusively for in-vitro laboratory research.

HIV-Associated Lipodystrophy

Most Effective

FDA-approved indication showing 15-20% visceral fat reduction in clinical trials.

Selective Visceral Fat Targeting

Most Effective

Unique mechanism that reduces dangerous visceral fat while sparing subcutaneous fat.

Sustained Fat Loss

Effective

Maintained weight loss with continuous treatment over 52+ weeks in clinical studies.

Triglyceride Reduction

Effective

12.3% reduction in triglyceride levels.

Cholesterol Profile Improvement

Effective

7.2% improvement in cholesterol markers.

NAFLD Treatment

Effective

37% liver fat reduction over 12 months.

Lean Mass Preservation

Moderate

Preserves lean muscle mass during fat loss.

IGF-1 Elevation

Moderate

26% increase in IGF-1 levels.

Dosing Protocols

injectable

Subcutaneous injection to abdomen (avoid navel ±2 inches). Evening injection preferred for GH circadian rhythm alignment.

Goal Dose Frequency Route
HIV Lipodystrophy (FDA-approved) 1.4mg Once daily SubQ
Visceral Fat Reduction 2mg Once daily SubQ
Anti-aging/Body Composition 1-2mg 5-7x weekly SubQ
NAFLD Treatment 2mg Once daily (12 months) SubQ
Cognitive Enhancement 1mg Once daily (20 weeks) SubQ

Key Tips

  • Abdomen (avoid navel ±2 inches)
  • Rotate injection sites
  • Evening injection preferred
Materials Needed
Tesamorelin lyophilized powder Sterile water (Egrifta SV) or Bacteriostatic water (Egrifta WR) Insulin syringes Alcohol prep pads
Steps
  1. 1 Allow vial to reach room temperature
  2. 2 Egrifta SV: Add 0.5mL sterile water to 2mg vial - use immediately
  3. 3 Egrifta WR: Add 1.3mL bacteriostatic water to 11.6mg vial - stable 7 days
  4. 4 Gently swirl (don't shake vigorously)
  5. 5 Withdraw appropriate dose (~0.35mL for 1.4mg)
  6. 6 Inject SubQ, rotating sites
  7. 7 Store reconstituted WR at room temperature up to 7 days

Peptide Interactions

Ipamorelin

Monitor

Synergistic GH stimulation; monitor IGF-1 levels.

CJC-1295

Monitor

Combined use may elevate IGF-1 supraphysiologically.

Sermorelin

Monitor

Similar mechanism; risk of excessive effects at higher doses.

Insulin

Monitor

3.3-fold diabetes risk increase; monitor glucose closely.

Metformin

Compatible

May mitigate glucose intolerance associated with tesamorelin.

Prednisone

Monitor

Decreases corticosteroid effectiveness.

Octreotide

Avoid

Blocks GH release, negates tesamorelin effects.

Growth Hormone

Avoid

Redundant; risk of acromegaly-like effects.

What to Expect

Week 1-2

IGF-1 levels begin to rise, possible mild water retention or joint discomfort

Week 4-6

Early metabolic changes; improved energy/sleep

Week 8-12

Visible visceral fat reduction begins, waist circumference may decrease

Week 12-26

Peak effects achieved with significant body composition improvements

Side Effects & Safety

Common Side Effects

  • Injection site reactions (17%)
  • Joint pain (13%)
  • Water retention

Monitoring

  • Monitor blood glucose regularly - 3.3-fold increased diabetes risk documented
  • IGF-1 levels should be checked monthly - 47% exceed normal range at 26 weeks

Stop Signs

  • Development of diabetes or severe glucose intolerance (HbA1c ≥6.5%)
  • Signs of malignancy
  • Severe hypersensitivity reactions
  • Excessive IGF-1 elevation (>2 SD above normal) with acromegaly symptoms

Contraindications

  • Active malignancy
  • Pituitary disorders
  • Pregnancy

Quality Checklist

Good Signs

  • FDA-approved formulations (Egrifta SV/WR from licensed pharmacy)
  • White crystalline powder (uniform, cake-like)
  • Clear reconstituted solution (colorless, no particles)
  • Proper packaging (sealed vials, intact stoppers)

Warning Signs

  • Compounded formulations may have quality/potency variability

Bad Signs

  • Discolored or cloudy solution (yellow/brown indicates degradation)
  • Visible particles or precipitate

Research & References

Key References

  1. 2010

    LIPO-010 FDA Pivotal Trial

    Significant visceral adipose tissue reduction (-24 ± 41 cm² vs +2 ± 35 cm² placebo, p < 0.001) in HIV patients over 26 weeks.

  2. 2011

    CTR-1011 Extended Safety Study

    69% achieved ≥8% VAT reduction vs 33% placebo at 26-52 weeks.

  3. 2019

    NAFLD Treatment Trial

    37% liver fat reduction over 12 months with fibrosis progression prevention.

  4. 2012

    Cognitive Enhancement Study

    Improved executive function and verbal memory in healthy elderly and mild cognitive impairment cohorts at 1mg daily.

Search PubMed for Tesamorelin

Research Library

Tesamorelin research & guides

Plain-English guides and study summaries from published literature.

View all 4
Low Growth Hormone and Ageing: Why It Matters Beyond Bodybuilding Guides 4 min

Low Growth Hormone and Ageing: Why It Matters Beyond Bodybuilding

Growth hormone is often treated as a niche topic for athletes, but many longevity discussions place it much closer to the centre of whole-body function. Here is a balanced look at why low growth hormone is frequently linked to poorer recovery, body-composition decline and slower ageing resilience.

Read article
The Only FDA-Approved “GH Peptide” for Fat Reduction (and how to use it intelligently) Guides 5 min

The Only FDA-Approved “GH Peptide” for Fat Reduction (and how to use it intelligently)

The Only FDA-Approved “GH Peptide” for Fat Reduction (and how to use it intelligently) Tesamorelin gets marketed as the “visceral fat peptide,” and compared to other growth-hormone peptides like CJC-1295 and sermorelin, it’s usually positioned as the top-tier option. Tesamorelin is the only one that’s actually FDA-approved for fat reduction (originally for HIV-associated lipodystrophy). That approval gives it a level of clinical legitimacy most other GH-related peptides simply don’t have.

Read article
Tesamorelin: is it really better for visceral fat? Guides 5 min

Tesamorelin: is it really better for visceral fat?

Tesamorelin gets called “the visceral fat peptide” because it’s the only growth-hormone–pathway peptide with real clinical data measuring visceral fat by CT scan in humans. Mechanistically, it’s doing the same core job as other GHRH analogs — it stimulates your pituitary to release growth hormone, which then drives IGF-1 — but the evidence base is what’s different, not some special visceral-fat-only switch.

Read article
The Solution: Tesamorelin Guides 5 min

The Solution: Tesamorelin

The Solution: Tesamorelin Don’t add the hormone. Fix the signal. The solution isn’t to pour in growth hormone from the outside. The solution is to fix the signal. Tesamorelin is not growth hormone. It’s the upstream command that tells your system to produce its own growth hormone the way it was designed to. This isn’t “here’s a fish.” It’s “here’s how to fish.”

Read article

Get Peptide Price-drop Alerts

Be the first to know when prices drop on your favourite peptides

Select peptides you're interested in:

No spam. Unsubscribe anytime. We respect your privacy.